Background and Aims: Inflammatory bowel diseases, principally Crohn's disease and ulcerative colitis, and celiac disease are among the most common immune-mediated gastrointestinal diseases. We aim to elucidate the clinical course and outcomes of patients with concomitant inflammatory bowel disease and celiac disease, a unique population that remains scarcely studied to date. Methods: A retrospective matched case-control study of adults with co-existent inflammatory bowel disease [IBD] and celiac disease was performed at a tertiary referral institution in North America. Logistic regression and Kaplan-Meier curves compared disease characteristics and clinical outcomes of the two groups. Results: A total of 342 inflammatory bowel disease patients were included in this study, of whom 114 had co-existent celiac disease and 228 did not. Patients with co-existent inflammatory bowel disease and celiac disease had higher rates of primary sclerosing cholangitis [19.3% vs 5.7%; odds ratio, 4.4; 95% confidence interval, 2.1-9.4; p <0.001], extensive ulcerative colitis [78.1% vs 59.0%; odds ratio, 2.8; 95% confidence interval, 1.5-5.5; p =0.002], and family history of celiac disease [10.5% vs 3.5%; odds ratio 3.2; 95% confidence interval, 1.3-8.2; p =0.01], compared with patients without concomitant celiac disease. Conclusions: Patients with inflammatory bowel disease with concomitant celiac disease have unique phenotypic features compared with non-celiac inflammatory bowel disease, with higher risks for colitis-related hospitalisations, extensive colitis, and primary sclerosing cholangitis. Increased recognition of co-existent IBD and celiac disease can prompt clinicians to investigate for concomitant disease sooner, particularly in patients with seemingly refractory disease.
Introduction
Inflammatory bowel diseases [IBD] , principally Crohn's disease [CD] and ulcerative colitis [UC] , and celiac disease are immune-mediated gastrointestinal diseases with complex interactions between genetic and environmental factors. 1 IBD and celiac disease have overlapping clinical features, including abdominal pain, diarrhoea, and malabsorption. 2 The prevalence of celiac disease in IBD is estimated to be 0.5-0.9%, 3, 4 similar to the prevalence of 0.8-1% in the general population. 4, 5 Conversely, approximately 1-3.2% of celiac disease patients have IBD, 4, 6, 7 a rate that is 3-10 times higher than the estimated IBD prevalence of 0.3% in the general population. 8, 9 IBD with concomitant celiac disease has not been extensively studied. To date, only one published retrospective case-control study has examined the phenotypic differences and outcomes of patients with IBD and concomitant celiac disease [IBD-Celiac] compared with non-celiac IBD individuals [IBD-only] . In that study, 2 pancolitis was more common in UC-Celiac patients compared with UC-only controls, though no differences were reported in CD behaviour or IBD-related medications, hospitalisations, and surgeries between the IBD-Celiac and IBD-only patient groups.
Whereas there is a complex interplay between genetic predisposition and environmental influence in the pathogenesis of IBD and celiac disease, the phenotypic overlap of these immune-mediated diseases has been under-explored. We herein aim to comprehensively analyse the interrelation between IBD and celiac disease with a matched case-control retrospective cohort study at a large tertiary referral centre in North America. In this study, we sought to determine the clinical course of IBD with concomitant celiac disease compared with patients with IBD alone; namely, the differences in disease phenotype, clinically relevant IBD outcomes, and extra-intestinal manifestations including primary sclerosing cholangitis [PSC].
Materials and Methods
With Institutional Review Board approval from the Mayo Foundation [protocol #16-007857], we conducted a retrospective case-control study conducted on patients from the Mayo Clinic's tri-campus [Minnesota, Florida, and Arizona]. Each UC/CD-Celiac study patient was matched by gender and IBD-subtype to two randomly selected IBD-only controls out of the pool of all IBD patients seen at the Mayo Clinic. Patients with a diagnosis of IBD-unclassified were excluded from further analysis. Potential cases and controls were identified through a query of an internal centralised data repository from 1997-2016, based on International Classification of Diseases [ICD] 9th and 10th edition diagnosis codes. Matched controls were identified based on the first appearance of ICD-9/10 diagnosis codes for IBD in our institution's electronic medical records; controls were matched +/-3 years of the study patients' IBD diagnosis date, based on the control pools' second date appearance of two ICD-9/10 codes identified at least 30 days apart [to limit the false-positives]. Review of the electronic medical records was performed to confirm the diagnosis of IBD based on the standard clinical, radiographic and histological criteria. 10, 11 For celiac disease, the diagnosis was made based on abnormal serum tests for IgA antibodies against tissue transglutaminase, gliadin, or endomysial antigens, and/or histological evidence of villous atrophy on duodenal biopsy. 12 Patients were excluded if they had microscopic colitis, negative HLA-DQ2 or HLA-DQ8 locus genetic analysis, or were <18 years old.
Baseline demographics, disease characteristics, and outcome variables were collected from the electronic medical records. The Montreal classification 13 was used to classify CD and UC phenotype. UC disease extent was further reclassified to limited UC [ulcerative proctitis and left sided UC] versus extensive UC [extensive UC and pancolitis] for statistical analysis. In this study, the UC extent was classified by the most extensive involvement known in the patient's history to reflect the UC phenotype, as the clinical course of UC can range from quiescent to fulminant disease with relapses interspersed with periods of remission.
14 Thus, in order to most accurately represent the phenotype of UC in the UC-Celiac and UC-only groups, we listed the most extensive UC involvement that was known in 
Results

Study population
A total of 448 patients with a diagnosis of both IBD and celiac disease were identified. A detailed review of the electronic medical records verified 117 IBD-Celiac study patients [n = 79 UC, n = 35 CD, and n = 3 IBD unclassified] who were then matched with 1:2 control patients [n = 158 UC and n = 70 CD]. Three patients with IBD-unclassified,, and 331 patients initially identified by ICD 9/10 coding but with either IBD or celiac disease diagnosis disconfirmed on review of electronic records [clinical notes and/or laboratory studies], were excluded from further analysis. The estimated proportion of IBD patients with concomitant celiac disease at our institution is 0.6%. The baseline characteristics of the IBD-Celiac study group and IBD-only control group are summarised in Table 1 [and in  Supplementary Table S1 , available as Supplementary data at ECCO-JCC online], comparing the CD-Celiac and UC-Celiac cohorts and their respective controls. As seen in Table 1, Family history of celiac disease was more common among IBD-Celiac patients compared with IBD-only controls (10 [7. 9%] of patients was concurrently diagnosed with IBD and celiac disease.
Extensive colitis is more common in UC patients with concomitant celiac disease
As seen in Table 1 , the presence of extensive colitis [versus limited colitis] was more common in UC-Celiac patients compared with UC-only controls [78.1% vs 59.0 %; OR, 2.8; 95% CI, 1.5-5.5; p = 0.002]. In contrast, no differences in location or phenotypic behaviour were found between CD-Celiac and CD-only patients [ Table 1 ].
Extra-intestinal manifestations, excluding PSC which was analysed separately, were less common among CD-Celiac patients compared with CD-only patients [8.6% vs 27.1%; OR, 0.3; 95% CI, 0.1-0.9; p = 0.04] but no differences were found among UC-Celiac and UC-only patients [ Table S1 ]. Figure 1 ]. For CD-Celiac and UC-Celiac study patients after time 0, the hazard ratios for PSC were 9.751 [95% CI, 0.9-107.6; p = 0.06] and 3.308 [95% CI, 0.9-12.8; p = 0.08] compared with CD-only and UC-only controls, respectively. In a sensitivity analysis that excluded IBD-celiac study patients with clinically diagnosed celiac disease and their respective matched IBD-only cohorts, the risk for PSC was also higher among IBD-Celiac study patients compared with IBD-only controls [ In a multivariate analysis with IBD diagnosis age, IBD duration, and UC extent, the presence of concomitant celiac disease with IBD continues to be associated with an increased risk for PSC [OR, 2.3; We observed no differences in the use of immunomodulators or biologics between the UC-Celiac and UC-only cohorts over a 5-year follow-up period following the initial presentation at our institution. However, we observed an increased usage of systemic steroids [19 
Higher PSC prevalence among IBD patients with co-existent celiac disease
95% CI, 1.02-5.3; p = 0.04] and decreased need for rescue steroids [
Discussion
Our study represents the largest case-control study to analyse the clinical course and phenotype of patients with IBD and concomitant celiac disease. Important findings of our study include the association of co-existent IBD-celiac with PSC, family history of celiac disease, and IBD-related hospitalisations. Patients with concurrent IBD and celiac disease were more likely to have IBD diagnosed first, and there was a delay of several years in the diagnosis of the other concomitant disease. Primary sclerosing cholangitis [PSC] is a chronic, autoimmune, cholestatic liver disease that is strongly associated with IBD. Up to 90% of patients with PSC have UC, 8, 15 and 5-7.5% of UC patients develop PSC during the course of their disease. 8, 16 The association between PSC and celiac disease is less clear. A large population-based study from Sweden found a 4-to 8-fold increase in the prevalence of PSC among individuals with celiac disease compared with non-celiac individuals in the general population, 17, 18 suggesting that there may be an association between these two immune-mediated gastrointestinal and hepatobiliary diseases.
A limited number of studies to date have examined the clinical association between IBD, celiac disease, and PSC, which are all believed to be immune-mediated disorders involving the gastrointestinal tract and the hepatobiliary system. A large Swedish epidemiological study found that first-degree relatives of PSC patients without IBD have a 7-fold risk for developing UC. 19 Our study found that patients with IBD and concurrent celiac disease were more likely to have PSC, a finding that was also noted in a few small case series. 20, 21 The association of PSC and UC with concomitant celiac disease, particularly those with pancolitis, could be related to common immunopathogenesis where gut-derived memory T-cells are recruited to the liver to induce biliary inflammation in PSC. 22, 23 Celiac disease and ulcerative colitis may share common polymorphisms in the receptor gene for IL-23, a major cytokine involved in Th17 cell differentiation. 24 Shared genetic risk loci for PSC and UC are under study. [24] [25] [26] Consequently, patients with UC and co-existent celiac disease may benefit from evaluation of co-existent PSC with laboratory screening tests and confirmatory evaluation with MRCP, ERCP, and/or liver biopsy.
IBD, celiac disease, and PSC may also share common environmental risk factors, such as vitamin D deficiency. Vitamin D metabolism is closely related to liver function as this is the site for enzymatic conversion of the inactive vitamin D3 to 25-hydroxy vitamin D3, a precursor to the active 1, 25-hydroxyvitamin D3. Vitamin D deficiency is common in patients with IBD, 27, 28 with a prevalence of up to 70% 29 and 45% 30 in CD and UC, respectively. Several studies have shown that 22-57% of PSC patients also had vitamin D deficiency, 31, 32 and that PSC was an independent factor for vitamin D deficiency in UC patients with ileal pouch-anal anastomosis [IPAA] . 33 The immunoregulatory properties of Vitamin D may be mediated by signalling through its receptor expressed in the gut. 34 Recent genome-wide association analysis has identified variation in vitamin D receptor, among several host factors influencing the gut microbiota. 35 In turn, the gut microbiota are essential for the metabolism of bile acids, 36 which acts as key vitamin D receptor ligands and regulate its expression. 37, 38 Further studies are needed to explore how vitamin D and other micronutrients may influence the clinical course of immune-mediated gastrointestinal diseases.
Our study findings may be limited by referral bias, and we attempted to minimise this by using a case-control design of patients who were identified from a common referral pool. The retrospective study design of our study also limits the availability, accessibility, and accuracy of data from existing electronic medical records. In future studies, age at IBD diagnosis could be considered as a matching factor, though this was not feasible in our study. Surveillance bias might contribute to residual confounding for family history of IBD or celiac disease [e.g., providers may be more likely to ask about family history in setting of celiac disease]. There is a possibility that some patients in our control group may have 'silent' or asymptomatic celiac disease. Nonetheless, previous studies have shown the expected prevalence of co-existent celiac disease among IBD patients to be 0.5-0.9% 3, 4 and hence unlikely to have influenced our results. Moreover, 8.8% of the IBD-Celiac study patients had an established celiac disease diagnosis before presentation at the Mayo Clinic, without further details on the previous diagnostic testing available in our database. This may lead to over-diagnosis of celiac disease and introduce bias to the results. Nonetheless, we were able to confirm celiac diagnosis by histology in the majority [81.4%] of study patients, which is considered by the American College of Gastroenterology to have a high level of evidence for the diagnosis of celiac disease. 12 Of note, our study has explored the order of diagnosis in patients with IBD and celiac disease, as well as the time-to-diagnosis of the concomitant disease. This is important, as a delay in making a diagnosis or a delay in the initiation of proper treatment in patients with co-existent IBD-Celiac disease may increase morbidity and even mortality. 39 It is, therefore, important to evaluate for co-existing celiac disease [e.g., by serology or histopathology] in IBD patients, particularly those with seemingly 'refractory' IBD who have ongoing clinical symptoms.
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